Show simple item record

AuthorHasan, Adria
AuthorKhan, Naushad Ahmad
AuthorUddin, Shahab
AuthorKhan, Abdul Q.
AuthorSteinhoff, Martin
Available date2025-04-16T05:09:34Z
Publication Date2024-01-31
Publication NameSeminars in Cancer Biology
Identifierhttp://dx.doi.org/10.1016/j.semcancer.2023.12.001
ISSN1044579X
URIhttps://www.sciencedirect.com/science/article/pii/S1044579X2300158X
URIhttp://hdl.handle.net/10576/64218
AbstractCancer progression is a multifaceted process that entails several stages and demands the persistent expression or activation of transcription factors (TFs) to facilitate growth and survival. TFs are a cluster of proteins with DNA-binding domains that attach to promoter or enhancer DNA strands to start the transcription of genes by collaborating with RNA polymerase and other supporting proteins. They are generally acknowledged as the major regulatory molecules that coordinate biological homeostasis and the appropriate functioning of cellular components, subsequently contributing to human physiology. TFs proteins are crucial for controlling transcription during the embryonic stage and development, and the stability of different cell types depends on how they function in different cell types. The development and progression of cancer cells and tumors might be triggered by any anomaly in transcription factor function. It has long been acknowledged that cancer development is accompanied by the dysregulated activity of TF alterations which might result in faulty gene expression. Recent studies have suggested that dysregulated transcription factors play a major role in developing various human malignancies by altering and rewiring metabolic processes, modifying the immune response, and triggering oncogenic signaling cascades. This review emphasizes the interplay between TFs involved in metabolic and epigenetic reprogramming, evading immune attacks, cellular senescence, and the maintenance of cancer stemness in cancerous cells. The insights presented herein will facilitate the development of innovative therapeutic modalities to tackle the dysregulated transcription factors underlying cancer.
SponsorThe study was supported by grant from the Medical Research Center (to Khan AQ; Grants MRC#0122-297, IRGC#06-NI-19-189), Hamad Medical Corporation, Doha, State of Qatar.
Languageen
PublisherElsevier
SubjectEmerging cancer hallmarks, transcription factors
Metabolic reprogramming, epigenetic reprogramming
Senescence
Therapeutic response
TitleDeregulated transcription factors in the emerging cancer hallmarks
TypeArticle
Pagination31-50
Volume Number98
ESSN1096-3650
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record